📊 MYO Key Takeaways
Is Myomo, Inc.. (MYO) a Good Investment?
MYOMO demonstrates strong revenue growth (25.7% YoY) and exceptional gross margins (68.2%), indicating viable product-market fit in the orthopedic device sector. However, deteriorating profitability with negative operating cash flow (-$2.2M), expanding net losses despite revenue growth (EPS -131.2% YoY), and elevated leverage (1.21x Debt/Equity) create material financial risk, particularly concerning for an unprofitable medical device company burning cash.
MYOMO shows strong revenue growth and a high gross margin, but remains deeply unprofitable with substantial negative free cash flow and worsening EPS. Leverage and severely negative interest coverage, alongside limited cash relative to annual burn, create near-term financing/dilution risk before scale is achieved. Fundamentals warrant caution until operating efficiency improves and cash burn moderates.
Myomo, Inc.. Key Strengths (MYO)
- Strong top-line growth at 25.7% YoY indicates market traction and demand for orthopedic products
- Exceptional gross margin of 68.2% demonstrates strong pricing power and/or manufacturing efficiency
- Adequate liquidity position with 2.73x current ratio and $11.4M cash reserves relative to $36.8M total assets
- 25.7% revenue growth indicating demand expansion
- High 65.7% gross margin supports potential operating leverage
- Solid liquidity with 3.30x current and 2.93x quick ratios
MYO Stock Risks: Myomo, Inc.. Investment Risks
- Worsening profitability: losses expanded despite revenue growth (EPS down 131.2% YoY), indicating negative operating leverage and cost control failure
- Negative operating and free cash flow (-$2.2M OCF, -$2.5M FCF) with ~4.5 year cash runway at current burn rate in an unprofitable state
- Elevated leverage (1.21x Debt/Equity, $10.9M long-term debt) combined with negative earnings and cash burn creates solvency risk if losses persist
- Persistent operating and net losses (-35% and -38% margins)
- Negative free cash flow and short runway versus cash on hand
- High leverage (0.98x D/E) and negative interest coverage increase refinancing/dilution risk
Key Metrics to Watch
- Operating cash flow trajectory - must inflect positive to validate business model sustainability
- Operating margin expansion path - current -31.2% margin must compress significantly for profitability
- Cash burn rate and runway - monitor if burn accelerates beyond current $2.5M annual FCF consumption rate
- Revenue growth deceleration impact - assess whether 25.7% growth can be sustained and if it generates positive cash at scale
- Operating cash flow (quarterly) / burn rate
- Operating margin trajectory toward break-even
Myomo, Inc.. (MYO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.73x current ratio provides a solid financial cushion.
MYO Profit Margin, ROE & Profitability Analysis
MYO vs Healthcare Sector: How Myomo, Inc.. Compares
How Myomo, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Myomo, Inc.. Stock Overvalued? MYO Valuation Analysis 2026
Based on fundamental analysis, Myomo, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Myomo, Inc.. Balance Sheet: MYO Debt, Cash & Liquidity
MYO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Myomo, Inc..'s revenue has grown significantly by 195% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.16 indicates the company is currently unprofitable.
MYO Revenue Growth, EPS Growth & YoY Performance
MYO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $9.8M | -$3.0M | $-0.07 |
| Q3 2025 | $9.2M | -$966.4K | $-0.03 |
| Q2 2025 | $7.5M | -$1.1M | $-0.03 |
| Q1 2025 | $3.8M | -$3.5M | $-0.08 |
| Q3 2024 | $5.1M | -$966.4K | $-0.03 |
| Q2 2024 | $6.0M | -$1.0M | $-0.03 |
| Q1 2024 | $3.4M | -$2.6M | $-0.10 |
| Q3 2023 | $4.0M | -$1.0M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Myomo, Inc.. Dividends, Buybacks & Capital Allocation
MYO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Myomo, Inc.. (CIK: 0001369290)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MYO
What is the AI rating for MYO?
Myomo, Inc.. (MYO) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 73% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MYO's key strengths?
Claude: Strong top-line growth at 25.7% YoY indicates market traction and demand for orthopedic products. Exceptional gross margin of 68.2% demonstrates strong pricing power and/or manufacturing efficiency. ChatGPT: 25.7% revenue growth indicating demand expansion. High 65.7% gross margin supports potential operating leverage.
What are the risks of investing in MYO?
Claude: Worsening profitability: losses expanded despite revenue growth (EPS down 131.2% YoY), indicating negative operating leverage and cost control failure. Negative operating and free cash flow (-$2.2M OCF, -$2.5M FCF) with ~4.5 year cash runway at current burn rate in an unprofitable state. ChatGPT: Persistent operating and net losses (-35% and -38% margins). Negative free cash flow and short runway versus cash on hand.
What is MYO's revenue and growth?
Myomo, Inc.. reported revenue of $10.1M.
Does MYO pay dividends?
Myomo, Inc.. does not currently pay dividends.
Where can I find MYO SEC filings?
Official SEC filings for Myomo, Inc.. (CIK: 0001369290) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MYO's EPS?
Myomo, Inc.. has a diluted EPS of $-0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is MYO's fundamental grade?
Based on our AI fundamental analysis in May 2026, Myomo, Inc.. has a C grade with 73% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is MYO stock overvalued or undervalued?
Valuation metrics for MYO: ROE of -33.4% (sector avg: 15%), net margin of -29.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is MYO's AI grade for 2026?
Our dual AI analysis gives Myomo, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MYO's free cash flow?
Myomo, Inc..'s operating cash flow is $-2.2M, with capital expenditures of $327.8K. FCF margin is -25.0%.
How does MYO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -29.8% (avg: 12%), ROE -33.4% (avg: 15%), current ratio 2.73 (avg: 2).